StockMarketWire.com - Morgan Stanley today reaffirms its underweight investment rating on GlaxoSmithKline PLC [LON:GSK] and cut its price target to 1725p (from 1740p).

Story provided by StockMarketWire.com

Broker Forecasts data provided by www.sharesmagazine.co.uk